Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
19 janv. 2021 17h06 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation...